Skip to main content
. 2010 Nov 15;28(36):5257–5264. doi: 10.1200/JCO.2010.29.2953

Fig 1.

Fig 1.

Favorable outcome of patients with FLT3-ITD and/or NPM1wt and higher miR-181a expression levels. (A) miR-181a expression in patients who achieved a complete response (CR) versus patients who did not achieve a CR; (B) disease-free and (C) overall survival according to miR-181a expression levels in patients with CN-AML dichotomized into high (above the median miR-181a expression value) or low (at or below the median miR-181a expression value) expression groups.